Lead Sponsor

Ottawa Hospital Research Institute

Collaborators

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

No

•1. Histologically confirmed female primary breast cancer patients whose surgery is planned for the next 2-8 weeks without neoadjuvant therapy as assessed by multidisciplinary team
•2. Age ≥18 years
•3. Clinically palpable tumour(s) (greater than or equal to 2 cm)
•4. Normal serum and urine calcium and serum PTH values at baseline (as defined by Ottawa Hospital)
•5. Written informed consent for study

•1. Patients with recurrent or metastatic breast cancer
•2. History of neoadjuvant hormonal therapy, chemotherapy, or radiation therapy in the last 6 months for their breast cancer or any other cancer treatment
•3. ECOG performance Status \> 2
•4. Hypercalciuria on initial baseline urine, defined as Ca/Creatinine Ratio\> 1.0
•5. Current or previous history of urolithiasis or hyperparathyroidism
•6. Abnormal hepatic function according to Ottawa Hospital norms (Total Bilirubin \>2x upper limit of normal, ALT/AST \>3x upper limit of normal)and/or abnormal renal function (Creatinine \> 150 µmol/L)
•7. History of granulomatous disease such as tuberculosis or sarcoidosis.
•8. Intake of Vitamin D (cholecalciferol) supplement ≥ 2000 IU/day within the last 2 months
•9. Inability to comply with a study protocol in the opinion of the investigator (such as abuse of alcohol, drugs or psychotic states).

Related studies

NCT06347068 · Breast Cancer, Relapse, and more

NCT06500481 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, and more

NCT07655934 · Breast Cancer

NCT07436078 · Female Breast Cancer, Prostate Cancer, and more

NCT06188520 · ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)

Effects of Vitamin D in Patients With Breast Cancer